Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Weisberg

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaXiaofei Liang, Beilei Wang, Cheng Chen, et al.
European Journal of Medicinal Chemistry|June 20, 2017
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitorsBeilei Wang, Yuanxin Deng, Yongfei Chen, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Oncotarget|April 14, 2016
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AMLAoli Wang, Hong Wu, Cheng Chen, et al.
Oncotarget|September 15, 2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Xiao-E Yan, Hong Wu, et al.
Cell Chemical Biology|November 14, 2017
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase DegraderHai-Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk, et al.
Leukemia|January 17, 2022
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2Jing Yang, Ellen L Weisberg, Shuang Qi, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Oncotarget|September 17, 2015
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsHong Wu, Aoli Wang, Wei Zhang, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaXiaofei Liang, Beilei Wang, Cheng Chen, et al.
European Journal of Medicinal Chemistry|June 20, 2017
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitorsBeilei Wang, Yuanxin Deng, Yongfei Chen, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Oncotarget|April 14, 2016
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AMLAoli Wang, Hong Wu, Cheng Chen, et al.
Oncotarget|September 15, 2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Xiao-E Yan, Hong Wu, et al.
Cell Chemical Biology|November 14, 2017
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase DegraderHai-Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk, et al.
Leukemia|January 17, 2022
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2Jing Yang, Ellen L Weisberg, Shuang Qi, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Oncotarget|September 17, 2015
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsHong Wu, Aoli Wang, Wei Zhang, et al.
Pageof 8